Latest Content

DT120 (lysergide) hits all endpoints in phase 3 GAD trial, cutting anxiety scores with a single dose.

Why modern psychiatry risks missing the person: It's time to revive biopsychosocial, cultural, and spiritual history beyond DSM checklists and EHR bloat.

New data show once-daily CTx-1301 delivers 3 timed dexmethylphenidate releases for faster onset, steadier late-day ADHD coverage, tolerability.

Explore new consensus guidelines on childhood stuttering, uniting psychiatry and neurology with practical treatment insights to improve patient care.

Review the latest developments in narcolepsy treatment.

Review the latest in psychiatry from the last week.

STARS experts redefine stuttering as a brain-based neuropsychiatric disorder, urging interdisciplinary care and warning dopamine-boosting ADHD or antidepressant meds may worsen symptoms.

Recognize postpartum psychosis fast: early signs, key risk factors, OCD vs delusions, and evidence-based lithium-centered treatment for urgent care.

Explore 2026 psychiatry practice M&A: surging demand, selective buyers, valuation premiums for scale, and the workforce/parity rules reshaping deals.

Explore suicide prevention in psychiatry—risk assessment, treatment challenges, and emerging research. Submit your case or CME for August 2026.

New case suggests muscarinic therapy xanomeline/trospium calms treatment‑resistant bipolar I mania with psychosis, hinting at nondopamine options.

Two psychiatrists use poetry and therapy to unpack clinician trauma, residency transformation, and how discomfort becomes a tool for patient connection.

Learn how clinicians tailor simple, measurable activity plans that boost depression and anxiety treatment—and improve long‑term adherence.